Tags

Type your tag names separated by a space and hit enter

Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
Biochem Biophys Res Commun. 2014 Dec 12; 455(3-4):347-52.BB

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a genetic disorder characterized by heterotopic endochondral ossification in soft tissue. A mutation in the bone morphogenetic protein (BMP) receptor ALK2, R206H, has been identified in patients with typical FOP. In the present study, we established murine embryonic stem (ES) cells that express wild-type human ALK2 or typical mutant human ALK2 [ALK2(R206H)] under the control of the Tet-Off system. Although wild-type ALK2 and mutant ALK2(R206H) were expressed in response to a withdrawal of doxycycline (Dox), BMP signaling was activated only in the mutant ALK2(R206H)-expressing cells without the addition of exogenous BMPs. The Dox-dependent induction of BMP signaling was blocked by a specific kinase inhibitor of the BMP receptor. The mutant ALK2(R206H)-carrying cells showed Dox-regulated chondrogenesis in vitro, which occurred in co-operation with transforming growth factor-β1 (TGF-β1). Overall, our ES cells are useful for studying the molecular mechanisms of heterotopic ossification in FOP in vitro and for developing novel inhibitors of chondrogenesis induced by mutant ALK2(R206H) associated with FOP.

Links

Publisher Full Text

Authors+Show Affiliations

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan; Division of Orthodontics, Department of Human Development and Fostering, Meikai University School of Dentistry, 1-1 Keyakidai, Sakado-shi, Saitama 350-0283, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan; Division of Orthodontics, Department of Human Development and Fostering, Meikai University School of Dentistry, 1-1 Keyakidai, Sakado-shi, Saitama 350-0283, Japan.

Division of Developmental Biology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

Division of Orthodontics, Department of Human Development and Fostering, Meikai University School of Dentistry, 1-1 Keyakidai, Sakado-shi, Saitama 350-0283, Japan.

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan. Electronic address: katagiri@saitama-med.ac.jp.

MeSH

Activin Receptors, Type IAnimalsBone Morphogenetic ProteinsCell DifferentiationChondrocytesChondrogenesisDisease Models, AnimalDoxycyclineEmbryonic Stem CellsHumansImmunohistochemistryMiceMutant ProteinsMutationMyositis OssificansSignal Transduction

Pub Type(s)

Journal Article

Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25446088

Citation

Fujimoto, Mai, et al. "Establishment of a Novel Model of Chondrogenesis Using Murine Embryonic Stem Cells Carrying Fibrodysplasia Ossificans Progressiva-associated Mutant ALK2." Biochemical and Biophysical Research Communications, vol. 455, no. 3-4, 2014, pp. 347-52.

Fujimoto M, Ohte S, Shin M, et al. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2. Biochem Biophys Res Commun. 2014;455(3-4):347-52.

Fujimoto, M., Ohte, S., Shin, M., Yoneyama, K., Osawa, K., Miyamoto, A., Tsukamoto, S., Mizuta, T., Kokabu, S., Machiya, A., Okuda, A., Suda, N., & Katagiri, T. (2014). Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2. Biochemical and Biophysical Research Communications, 455(3-4), 347-52. https://doi.org/10.1016/j.bbrc.2014.11.012

Fujimoto M, et al. Establishment of a Novel Model of Chondrogenesis Using Murine Embryonic Stem Cells Carrying Fibrodysplasia Ossificans Progressiva-associated Mutant ALK2. Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):347-52. PubMed PMID: 25446088.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2. AU - Fujimoto,Mai, AU - Ohte,Satoshi, AU - Shin,Masashi, AU - Yoneyama,Katsumi, AU - Osawa,Kenji, AU - Miyamoto,Arei, AU - Tsukamoto,Sho, AU - Mizuta,Takato, AU - Kokabu,Shoichiro, AU - Machiya,Aiko, AU - Okuda,Akihiko, AU - Suda,Naoto, AU - Katagiri,Takenobu, Y1 - 2014/11/15/ PY - 2014/10/28/received PY - 2014/11/07/accepted PY - 2014/12/3/entrez PY - 2014/12/3/pubmed PY - 2015/2/11/medline KW - BMP receptor KW - Chondrocytes KW - Embryonic stem cells KW - Fibrodysplasia ossificans progressiva SP - 347 EP - 52 JF - Biochemical and biophysical research communications JO - Biochem Biophys Res Commun VL - 455 IS - 3-4 N2 - Fibrodysplasia ossificans progressiva (FOP) is a genetic disorder characterized by heterotopic endochondral ossification in soft tissue. A mutation in the bone morphogenetic protein (BMP) receptor ALK2, R206H, has been identified in patients with typical FOP. In the present study, we established murine embryonic stem (ES) cells that express wild-type human ALK2 or typical mutant human ALK2 [ALK2(R206H)] under the control of the Tet-Off system. Although wild-type ALK2 and mutant ALK2(R206H) were expressed in response to a withdrawal of doxycycline (Dox), BMP signaling was activated only in the mutant ALK2(R206H)-expressing cells without the addition of exogenous BMPs. The Dox-dependent induction of BMP signaling was blocked by a specific kinase inhibitor of the BMP receptor. The mutant ALK2(R206H)-carrying cells showed Dox-regulated chondrogenesis in vitro, which occurred in co-operation with transforming growth factor-β1 (TGF-β1). Overall, our ES cells are useful for studying the molecular mechanisms of heterotopic ossification in FOP in vitro and for developing novel inhibitors of chondrogenesis induced by mutant ALK2(R206H) associated with FOP. SN - 1090-2104 UR - https://www.unboundmedicine.com/medline/citation/25446088/Establishment_of_a_novel_model_of_chondrogenesis_using_murine_embryonic_stem_cells_carrying_fibrodysplasia_ossificans_progressiva_associated_mutant_ALK2_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-291X(14)02015-4 DB - PRIME DP - Unbound Medicine ER -